TI
ATXI

Trexquant Investment’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Trexquant Investment’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12
Closed -$84K – 1574
2021
Q1 		$84K Buy
+12
New +$82.5K 0.01% 1063

Other funds holding ATXI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Trexquant Investment's ATXI Position: Q2 2021 in Review

Trexquant Investment sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q2 2021, closing a stake of 12 shares — an estimated $84K sold.

Trexquant Investment first reported a position in ATXI in Q1 2021 and held it in 1 quarter. The position peaked at $84K in Q1 2021. 24 funds tracked by Wall St. Rank hold ATXI as of Q2 2021.

  • Trexquant Investment reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Trexquant Investment sold 12 Avenue Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $84K.
  • Trexquant Investment first reported a position in Avenue Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Trexquant Investment's Avenue Therapeutics, Inc. Common Stock position peaked at $84K in Q1 2021.
  • 24 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Trexquant Investment's 13F filing for Q2 2021, filed 12 Aug 2021.